ABUS 2Q22 results—6/30/22 cash=$200.6M—(down from $222M @3/31/22):
Chardan Capital Reaffirms Their Buy Rating on Arbutus Biopharma (ABUS) • TipRanks • 06/28/2022 11:55:13 AM
Current Report Filing (8-k) • Edgar (US Regulatory) • 06/27/2022 01:01:27 PM
Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update • GlobeNewswire Inc. • 06/25/2022 08:05:00 AM
ABUS’ AB-836 HBV capsid inhibitor shows_safety_signal_in_phase-1b_trial—see slide #18 from today’s EASL CC:
As a result of the safety signal, ABUS will rerun a phase-1a trial (i.e. retest healthy volunteers) to gain further insight on the relevance of the signal.
ABUS, VACC start phase-2a trial of AB-729 + VTP-300 + nuc in virologically-suppressed HBV patients:
MRNA seeks_dismissal of ABUS patent-infringement suit on_legal_technicality:
ABUS cash @3/31/22=$222M, up $31M from 12/31/21 due to the Qilu deal announced in December that closed during 1Q22 (#msg-167103305); 1Q22 operating cash burn was $23M:
ABUS reiterated guidance for 2022 operating cash burn of $90-95M. Thanks to the cash inflow from the Qilu deal, ABUS tapped its ATM facility only minimally during 1Q22, raising $0.3M.
March 18, 2022 02:29 PM ET (BZ Newswire) -- Biotech
Canada-based Acuitas Therapeutics Inc has sued Arbutus Biopharma Corporation (NASDAQ:ABUS) in Manhattan federal court, seeking to head off claims that the vaccine infringes Arbutus' patents, reports Reuters.
Acuitas, Canada-based biotech, makes mRNA-delivery technology for Pfizer Inc's (NYSE:PFE) COVID-19 vaccine.
Acuitas said Arbutus and partner Genevant Sciences have threatened to sue for potentially billions of dollars in "unjustified royalties" over the vaccine Pfizer developed in partnership with BioNTech SE (NASDAQ:BNTX).
Acuitas asked the court to find that the Pfizer/BioNTech vaccine does not infringe on Arbutus patents and that several are invalid.
Acuitas Chief Executive Thomas Madden said that the company remains confident in its technology but otherwise declined to comment on the lawsuit.
Last month, Arbutus sued Moderna Inc (NASDAQ:MRNA) over its mRNA technology but had not yet sued Pfizer or Acuitas.
Pfizer and Moderna were hit with patent lawsuits Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) argued its lipid nanoparticle mRNA-delivery technology was "essential" to both of the widely used COVID-19 vaccines.
Price Action: ABUS shares are up 2.15% at $3.09, PFE stock is down 0.13% at $54.17 during the market session on the last check Friday.
Copyright © 2022 Benzinga (BZ Newswire, http://www.benzinga.com/licensing). Benzinga does not provide investmentadvice. All rights reserved.
Write to firstname.lastname@example.org with any questions about this content. Subscribe to Benzinga Pro (http://pro.benzinga.com).
The ABUS-Antios HBV trial_has_been_truncated_by_ war_in Ukraine; from ABUS’ 4Q21 PR:
ABUS 4Q21 financials:
At 12/31/21, the cash and marketable securities balance was $191M, thanks to aggressive use of the ATM facility during 2021. (The $191M figure does not include the $55M up-front amount from the collaboration with Qilu Pharmaceutical announced in Dec 2021: #msg-167103305). ABUS’ 2022 cash-burn guidance is $90-95M.
why take so long filing ????? corporate news still drove the action in many individual stocks, with a lawsuit related to COVID vaccines presenting one of the biggest stories. Arbutus (NASDAQ:ABUS) jumped before the opening bell after filing a patent lawsuit against COVID vaccine maker Moderna (NASDAQ:MRNA).
On February 28, 2022, Arbutus Biopharma Corporation (the "Company") and Genevant Sciences filed a lawsuit in the U.S. District Court for the District of Delaware against Moderna, Inc. (Nasdaq: MRNA) and a Moderna affiliate seeking damages for infringement of U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of MRNA-1273, Moderna’s vaccine for COVID-19. The patents relate to nucleic acid-lipid particles and lipid vesicles, as well as compositions and methods for their use.
Then why is it down
WEDNESDAY, FEBRUARY 2, 2022 | MARKETBEAT Arbutus Biopharma (NASDAQ:ABUS) was upgraded by stock analysts at Jefferies Financial Group from a "hold" rating to a "buy" rating in a report issued on Wednesday, Briefing.com reports. The firm currently has a $5.00 target price on the biopharmaceutical company's stock. Jefferies Financial Group's price target indicates a potential upside of 71.23% from the stock's current price.
ABUS has been the topic of a number of other reports. JMP Securities lifted their price objective on shares of Arbutus Biopharma from $7.00 to $9.00 and gave the stock a "market outperform" rating in a report on Monday, November 8th. Chardan Capital upped their price target on Arbutus Biopharma from $5.00 to $5.50 and gave the company a "buy" rating in a research report on Thursday, December 2nd. Zacks Investment Research upgraded shares of Arbutus Biopharma from a "hold" rating to a "buy" rating and set a $4.00 price objective on the stock in a research report on Monday, January 10th. Finally, HC Wainwright cut their target price on Arbutus Biopharma from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Monday, November 8th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Arbutus Biopharma has a consensus rating of "Buy" and a consensus target price of $6.42.
NASDAQ:ABUS opened at $2.92 on Wednesday. Arbutus Biopharma has a 52 week low of $2.38 and a 52 week high of $6.50. The firm has a market cap of $394.99 million, a price-to-earnings ratio of -3.21 and a beta of 2.74. The firm's 50-day simple moving average is $3.58 and its 200 day simple moving average is $3.5
Arbutus Biopharma (NASDAQ:ABUS) last released its quarterly earnings results on Thursday, November 4th. The biopharmaceutical company reported ($0.24) EPS for the quarter, hitting analysts' consensus estimates of ($0.24). The business had revenue of $3.34 million for the quarter, compared to the consensus estimate of $2.36 million. During the same period in the prior year, the business posted ($0.27) earnings per share. As a group, analysts anticipate that Arbutus Biopharma will post -0.86 EPS for the current fiscal year.
Institutional investors have recently made changes to their positions in the company. BlackRock Inc. boosted its holdings in Arbutus Biopharma by 1.7% during the 3rd quarter. BlackRock Inc. now owns 5,935,203 shares of the biopharmaceutical company's stock valued at $25,463,000 after acquiring an additional 99,630 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Arbutus Biopharma by 31.9% in the 2nd quarter. Vanguard Group Inc. now owns 3,736,233 shares of the biopharmaceutical company's stock worth $11,321,000 after buying an additional 904,006 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Arbutus Biopharma by 19.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,540,431 shares of the biopharmaceutical company's stock worth $6,608,000 after buying an additional 253,773 shares during the period. State Street Corp lifted its holdings in shares of Arbutus Biopharma by 1,942.2% in the 2nd quarter. State Street Corp now owns 1,156,094 shares of the biopharmaceutical company's stock worth $3,503,000 after buying an additional 1,099,484 shares during the period. Finally, Two Sigma Investments LP lifted its holdings in shares of Arbutus Biopharma by 187.7% in the 3rd quarter. Two Sigma Investments LP now owns 730,298 shares of the biopharmaceutical company's stock worth $3,133,000 after buying an additional 476,475 shares during the period. Hedge funds and other institutional investors own 54.51% of the company's stock.
Which 8-K filing are you referring to?
CASH-COW $ABUS Current Report Filing (8-k)
January 24 2022 - 07:32AM
Edgar (US Regulatory)
Share On Facebook
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 24, 2022
Arbutus Biopharma Corporation
(Exact name of registrant as specified in its charter)
British Columbia, Canada 001-34949 98-0597776
(State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
701 Veterans Circle
Warminster, Pennsylvania 18974
(Address of Principal Executive Offices) (Zip Code)
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
? Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
? Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
? Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
? Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Shares, without par value ABUS The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ?
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ?
Item 2.02. Results of Operations and Financial Condition.
On January 24, 2022, Arbutus Biopharma Corporation (the "Company") issued a press release (the "Press Release") announcing its 2022 corporate objectives and providing certain estimated and projected financial information, including its estimated cash, cash equivalents and investments as of December 31, 2021. The amounts included in the Press Release are preliminary, have not been audited and are subject to change upon completion of the Company's audited financial statements for the year ended December 31, 2021. Additional information and disclosures would be required for a more complete understanding of the Company's financial position and results of operations as of December 31, 2021. A copy of the Press Release is furnished as Exhibit 99.1 hereto.
On January 24, 2022, the Company posted an updated corporate presentation on its website at www.arbutusbio.com (the "Corporate Presentation"), which included the Company's estimated cash, cash equivalents and investments as of December 31, 2021. A copy of the Corporate Presentation is furnished as Exhibit 99.2 hereto.
Item 8.01. Other Events.
On January 24, 2022, the Company issued the Press Release, a copy of which is filed herewith as Exhibit 99.1 hereto and is incorporated by reference herein.
A copy of the Corporate Presentation is attached hereto as Exhibit 99.2 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
Exhibit Number Description
99.1 Press Release dated January 24, 2022
99.2 Corporate Presentation January 24, 2022
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Arbutus Biopharma Corporation
Date: January 24, 2022 By: /s/ David C. Hastings
David C. Hastings
Chief Financial Officer
$ABUS cash-cow 01-24-2022 Financial position significantly strengthened; cash runway into Q2 2024
i like da read --- #2 $ABUS Multiple AB-729 and AB-836 HBV clinical data readouts anticipated to guide future clinical development and regulatory strategies
Complete IND-enabling studies for oral PD-L1 inhibitor, AB-101, for the treatment of HBV
Complete IND-enabling studies for next generation oral RNA destabilizer, AB-161, for the treatment of HBV
Advance an nsp5 main protease (Mpro) inhibitor candidate into IND-enabling studies for treatment of SARS-CoV-2
Financial position significantly strengthened; cash runway into Q2 2024
WARMINSTER, Pa., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced its 2022 corporate objectives and provided a financial update.
William Collier, President and CEO, stated, “This year is an important one for Arbutus and the HBV patient community based on the many accomplishments we achieved in 2021. With five clinical trials on-going in HBV that include either AB-729 or AB-836, we are now poised for several key data readouts throughout this year that we anticipate will support Phase 2b clinical development. In addition, we intend to advance AB-101, our oral PD-L1 inhibitor compound for HBV which is designed to re-awaken the immune system, through IND-enabling studies this year. Similarly, this year we intend to complete IND-enabling studies for our RNA destabilizer, AB-161.”
Mr. Collier continued, “As the COVID-19 pandemic lingers, we are expediting our efforts to advance novel oral pan-coronavirus compounds against viral protease and polymerase targets. We intend to advance an Mpro candidate into IND-enabling studies for the treatment of SARS-CoV-2 this year.
“Lastly, we are entering 2022 from a position of financial strength, with a cash runway expected to extend into the second quarter of 2024. I am thrilled with the company’s accomplishments and execution in 2021 and look forward to providing further updates over the course of this coming year.”
Summary of 2022 Anticipated Key Milestones:
Announce preliminary AB-729 data in the second half of 2022 from the following three on-going Phase 2a proof-of-concept clinical trials in patients with chronic hepatitis B (HBV) infection:
AB-729 in combination with ongoing standard-of-care nucleos(t)ide analogues (“NA”) therapy and short courses of PEG-IFNa-2a.
AB-729 plus vebicorvir (“VBR”), Assembly Bio’s lead investigational HBV core inhibitor (capsid inhibitor) candidate, and a NA.
AB-729 plus ATI-2173, Antios’ proprietary Active Site Polymerase Inhibitor Nucleotide (ASPIN), and Viread® (tenofovir disoproxil fumarate).
Initiate a triple combination Phase 2a proof-of-concept clinical trial in the first half of 2022 to evaluate AB-729, combined with VTP-300, Vaccitech’s therapeutic vaccine, and a NA.
Present at a medical conference the long-term on- and off-treatment follow-up data from our Phase 1a/1b clinical trial evaluating multiple doses and dosing schedules of AB-729.
Announce data from our Phase 1a/1b clinical trial evaluating AB-836 in patients with chronic HBV in the first half of 2022.
Complete IND-enabling studies with our oral PD-L1 inhibitor compound, AB-101, in the second half of 2022.
Complete IND-enabling studies for AB-161, our next-generation oral HBV specific RNA destabilizer, in the second half of 2022. Arbutus has conducted extensive non-clinical safety evaluations with AB-161 that gives us confidence in this molecule’s ability to circumvent the peripheral neuropathy findings seen in non-clinical safety studies with the Company’s first-generation oral RNA destabilizer, AB-452.
COVID-19 & Pan-Coronavirus Franchise
Nominate a candidate that inhibits the SARS-CoV-2 nsp5 main protease (Mpro) in the first half of 2022 and advance into IND-enabling studies.
Continue lead optimization activities for an Nsp12 viral polymerase candidate.
Explore potential oncology applications for internal PD-L1 portfolio.
We had cash, cash equivalents and investments in marketable securities totaling $191 million as of December 31, 2021. This amount does not include a $40 million upfront payment and $15 million of proceeds resulting from the sale of common stock to Qilu Pharmaceutical as part of the exclusive licensing agreement and strategic partnership to develop and commercialize AB-729 in mainland China, Hong Kong, Macau and Taiwan. These amounts were received in January 2022.
For the full year of 2021 we received $135 million of net proceeds from the issuance of common shares under Arbutus’s “at-the-market” offering program. As of December 31, 2021, we had approximately 145 million common shares issued and outstanding, and approximately 11.4 million stock options outstanding.
We expect our net cash burn to range from $90 to $95 million in 2022. We believe our cash, cash equivalents and investments in marketable securities of $191 million as of December 31, 2021, plus the amounts received from Qilu Pharmaceutical in January 2022 are sufficient to fund the Company’s operations into the second quarter of 2024.
The preliminary cash, cash equivalents and investments, the amount received from the issuance of common shares under Arbutus’s “at-the-market” offering program and the common shares and stock options outstanding as of December 31, 2021 were calculated prior to the completion of an audit by Arbutus’ independent registered public accounting firm and are therefore subject to adjustment.
In December 2019 an outbreak of a novel strain of coronavirus (COVID-19) was identified in Wuhan, China. This virus has been declared a pandemic by the World Health Organization and has spread to nearly every country in the world. The impact of this pandemic has been, and will likely continue to be, extensive in many aspects of society. The pandemic has resulted in and will likely continue to result in significant disruptions to businesses. A number of countries and other jurisdictions around the world have implemented extreme measures to try and slow the spread of the virus. These measures include the closing of businesses and requiring people to stay in their homes, the latter of which raises uncertainty regarding the ability to travel to hospitals in order to participate in clinical trials. Additional measures that have had, and will likely continue to have, a major impact on clinical development, at least in the near-term, include shortages and delays in the supply chain, and prohibitions in certain countries on enrolling subjects and patients in new clinical trials. While we have been able to progress with our clinical and pre-clinical activities to date, it is not possible to predict if the COVID-19 pandemic will materially impact our plans and timelines in the future.
AB-729 is an RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral proteins and antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus. AB-729 targets hepatocytes using Arbutus’ novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology that enables subcutaneous delivery. Clinical data generated thus far has shown single- and multi-doses of AB-729 to be generally safe and well-tolerated while providing meaningful reductions in hepatitis B surface antigen and hepatitis B DNA. AB-729 is currently in multiple Phase 2a clinical trials.
AB-836 is a next generation oral hepatitis B virus (HBV) capsid inhibitor that interacts with HBV core protein, which in turn is required for viral replication. The current standard-of-care therapy for HBV is primarily nucleos(t)ide analogues that inhibit the viral polymerase and significantly reduce, but do not eliminate viral replication. AB-836 in combination with nucleos(t)ide analogues is designed to completely eliminate viral replication in infected cells by preventing the assembly of functional viral capsids. In addition, AB-836 has been shown to inhibit the replenishment of covalently closed circular DNA (cccDNA), the viral genetic reservoir which the virus needs to replicate itself. Preliminary data from an on-going Phase 1a/1b clinical trial has shown that AB-836 is generally safe and well-tolerated and provides robust antiviral activity.
Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). HBV can cause chronic infection which leads to a higher risk of death from cirrhosis and liver cancer. Chronic HBV infection represents a significant unmet medical need. The World Health Organization estimates that over 250 million people worldwide suffer from chronic HBV infection, while other estimates indicate that approximately 2 million people in the United States suffer from chronic HBV infection. Approximately 900,000 people die every year from complications related to chronic HBV infection despite the availability of effective vaccines and current treatment options.
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. Our current focus areas include Hepatitis B virus (HBV) and coronaviruses. In HBV, we are developing a RNAi therapeutic, oral capsid inhibitor, oral PD-L1 inhibitor, and oral RNA destabilizer that we intend to combine to improve the outcomes of patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. Our lead compound, AB-729 is the only RNAi therapeutic with evidence of immune re-awakening and is currently being evaluated in multiple phase 2 clinical trials. We have an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronavirus (including COVID-19). We are also exploring oncology applications for our internal PD-L1 portfolio. For more information, visit www.arbutusbio.com.
Forward-Looking Statements and Information
This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements in this press release include statements about our future development plans for our product candidates; the expected cost, timing and results of our clinical development plans and clinical trials with respect to our product candidates; our expectations and goals for our collaborations with third parties and any potential benefits related thereto; the potential for our product candidates to achieve success in clinical trials; our expected financial condition, including the anticipated duration of cash runways and timing regarding needs for additional capital; and our expectations regarding the impact of the COVID-19 pandemic on our business and clinical trials.
With respect to the forward-looking statements contained in this press release, Arbutus has made numerous assumptions regarding, among other things: the effectiveness and timeliness of preclinical studies and clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; the continued demand for Arbutus’ assets; and the stability of economic and market conditions. While Arbutus considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies, including uncertainties and contingencies related to the ongoing COVID-19 pandemic.
Additionally, there are known and unknown risk factors which could cause Arbutus’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: anticipated pre-clinical studies and clinical trials may be more costly or take longer to complete than anticipated, and may never be initiated or completed, or may not generate results that warrant future development of the tested product candidate; Arbutus may elect to change its strategy regarding its product candidates and clinical development activities; Arbutus may not receive the necessary regulatory approvals for the clinical development of Arbutus’ products; economic and market conditions may worsen; Arbutus and its collaborators may never realize the expected benefits of the collaborations; market shifts may require a change in strategic focus; and the ongoing COVID-19 pandemic could significantly disrupt Arbutus’ clinical development programs.
A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus’ Annual Report on Form 10-K, Arbutus’ Quarterly Reports on Form 10-Q and Arbutus’ continuous and periodic disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.
Investors and Media
William H. Collier
President and CEO
Lisa M. Caperelli
Vice President, Investor Relations
Arbutus Announces 2022 Corporate Objectives and Provides Financial Update
Arbutus Biopharma Corporation
Mon, January 24, 2022, 5:30 AM
MRNA PFE BNTX COURT FILING WON BY ABUS AGAINST MRNA PFE BNTX NVAX
MRNA COULD COULD GO BELOW $100 OR MORE IN 2022 !!!!!
Reviewing 12-08-2021 $ABUS/ GenevantFACTS: & $ABUS WOW FOR INFRINGEMENT OF PATENTS PFE BNTX MRNA NVAX , OTHERS CONTINUES TO GROW !!!!!
COURT DENIED $MRNA APPEAL;
BUY;Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment 11-19-2021
*Arbutus shares are trading higher after The Patent Trial and Appeals Board has turned down Moderna's appeal to invalidate two of Arbutus' patents on drug-delivery technology.
$ABUS Preliminary Data Shows that Arbutus’ Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity
December 01 2021 - 11:58AM
Share On Facebook
1) May 4th Appeals Briefs due in MRNA vs ABUS 069. Oral next. ABUS asked for extension.ABUS
1) May 4th Appeals Briefs due in MRNA vs ABUS 069. Oral next. ABUS asked for extension.
2) May 5th. HBV Virtual Summit
3) May 10ish 2021, Expected Q1 Earnings Report. Has NOT been announced but was May 11, 2020
4) NO major PR since mid March, PR challenged. Last HBV trial news was Dec. 10th, 90 days was due March 10th
5) Annual Meeting email sent April 22nd. Meeting May 23rd
6) Requested 9M shares in Comp. Plan in 2021 vs 3M in 2020.
Offering last meeting. ATM. At $3.75/share, that's 20,000,000 shares. Averaged 2M a month from Oct 2020 to March 2021.
OS rose from 85M to 96M
8) October 2021, MANDATORY conversion of preferred shares owned by Roivant for repayment of loan 5 years ago.
24 million shares at $7. Roivant/Vivek will then own 40M ABUS shares.
9) Oct, 2021 - 5 year "No Buy" expires. Roivant can buy ABUS shares
10) Sophie developed cure for HepC!
11) Pipeline!!! AB 729 PT COVID P1 ends 4/30
$ABUS WOW FOR DIS INFRINGEMENT OF PATENTS MRNA CONTINUES TO GROW !!!!!
MarketWatch • 2 hours ago
U.S. buys another 100 million COVID-19 vaccine candidate doses:
IS VERY SUCCEESSFUL SO FAR IN THEIR VACCINE